The Middle East and Africa generic injectables market was valued at USD 0.90 Billion in 2024, driven by the growing demand for cost-effective healthcare solutions and growth in local generic manufacturing capabilities in the region. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2025-2034, reaching a value of USD 1.91 Billion by 2034 .
The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which has substantially affected the market demand. Recent data reveals that the size of the pharmaceutical market in Saudi Arabia has witnessed a massive increase, with most of the national pharmaceutical industries focused on the production of generics. Additionally, local manufacturing of generic injectables was estimated to be 30% out of all dosage forms in the region. This growth of local generic pharmaceutical manufacturing capabilities and capacities, supported by both public and private investments, is projected to boost the Middle East and Africa generic injectables market share.
One of the major market trends is the rise in strategic partnerships between public and private bodies to address global health challenges. For instance, in March 2023, multinational pharmaceutical company GlaxoSmithKline (GSK plc) issued voluntary licenses to three companies (Aurobindo Pharma, Cipla, and Viatris) to manufacture generic versions of its HIV preventive medicine (injectable drug cabotegravir). This deal is likely to expedite market penetration of this injectable in lower-income countries. Further, Indian drugmaker Cipla reported plans to manufacture the generic injection in South Africa. Moreover, GSK also announced a public-private partnership with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026. Such licensing agreements indicate an emphasis on increasing access to cost-effective medications which is anticipated to elevate the market value in the forecast period.
Other players in the market include Viatris Inc., and Sanofi, among others.>
This product will be delivered within 3-5 business days.
Middle East and Africa Generic Injectables Market Analysis
Generic injectables are high-quality bioequivalent versions of expensive innovator injectables, typically marketed at a lower price. These pharmaceutical products are injected either by a healthcare worker or the patients themselves and are used in certain clinical settings such as cancer care, trauma, and surgery, due to their rapid onset of action and higher bioavailability. There is a growing focus on the development of novel formulations of these faster-acting generics in oncology and specialty therapeutic areas, which is influencing the global generic injectables market landscape. Further, several generic manufacturers are increasingly investing in expanding their generic injectable portfolio to meet the growing healthcare demand, which is expected to fuel the Middle East and Africa generic injectables market growth.The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which has substantially affected the market demand. Recent data reveals that the size of the pharmaceutical market in Saudi Arabia has witnessed a massive increase, with most of the national pharmaceutical industries focused on the production of generics. Additionally, local manufacturing of generic injectables was estimated to be 30% out of all dosage forms in the region. This growth of local generic pharmaceutical manufacturing capabilities and capacities, supported by both public and private investments, is projected to boost the Middle East and Africa generic injectables market share.
One of the major market trends is the rise in strategic partnerships between public and private bodies to address global health challenges. For instance, in March 2023, multinational pharmaceutical company GlaxoSmithKline (GSK plc) issued voluntary licenses to three companies (Aurobindo Pharma, Cipla, and Viatris) to manufacture generic versions of its HIV preventive medicine (injectable drug cabotegravir). This deal is likely to expedite market penetration of this injectable in lower-income countries. Further, Indian drugmaker Cipla reported plans to manufacture the generic injection in South Africa. Moreover, GSK also announced a public-private partnership with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026. Such licensing agreements indicate an emphasis on increasing access to cost-effective medications which is anticipated to elevate the market value in the forecast period.
Middle East and Africa Generic Injectables Market Segmentation
The report titled “Middle East and Africa Generic Injectables Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:Market Breakup by Product Type
- Large Molecule Injectables
- Small Molecule Injectables
Market Breakup by Container Type
- Vials
- Premix
- Prefilled Syringes
- Ampoules
- Others
Market Breakup by Application
- Oncology
- Cardiovascular
- CNS
- Infectious Diseases
- Autoimmune Disorders
- Others
Market Breakup by Route of Administration
- Intravenous
- Intramuscular
- Subcutaneous
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Market Breakup by Region
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Leading Players in the Middle East and Africa Generic Injectables Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:Pfizer Inc.
Pfizer has a strong presence in the sterile injectables industry, with a range of offerings in generic and branded products. To expand its market presence in the generic injectables sector, it acquired a leading manufacturer of injectable drugs and infusion technologies, Hospira, in 2015.Baxter
A global leader in generic injectables, Baxter International Inc., is actively engaged in strategic mergers and acquisition activities to bolster the development of generic injectables in various therapeutic categories.Hikma Pharmaceuticals PLC
This British multinational pharmaceutical company is known for its non-branded generic and in-licensed products. It is a leading supplier of injectable pharmaceuticals in the Middle East and North African countries and is focusing on expanding local manufacturing operations in the region.Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, is a prominent player in the market. It specializes in developing generic formulations, including injectables, tablets, capsules, and topical creams across the major therapeutic areas.Other players in the market include Viatris Inc., and Sanofi, among others.>
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Middle East and Africa Generic Injectables Market Overview
4 Middle East and Africa Generic Injectables Market Landscape*
5 Middle East and Africa Generic Injectables Market Dynamics
6 Middle East and Africa Generic Injectables Market Segmentation (2018-2034)
7 Saudi Arabia Generic Injectables Market (2018-2034)
8 United Arab Emirates Generic Injectables Market (2018-2034)
Companies Mentioned
- Pfizer Inc.
- Baxter
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd.
